Therefore, we hypothesize that SERPINA1 hypermethylation may represent a risk factor for developing COPD in ACS patients at risk (smokers) with high levels of circulating lymphocytes in the presence of pharmacological treatments following percutaneous coronary intervention. Here, SERPINA1 is linked to chronic obstructive pulmonary disease.